Topics:
Gynecologic Cancers • Medical Oncology
What would you offer a patient with MSI-high metastatic endometrial cancer after disease progression on pembrolizumab?
The patient was initially treated with Carboplatin/Paclitaxel and progressed after 1 year. She was switched to pembrolizumab and had significant progression after 1 year. Would you consider rechallenging her with platinum therapy, adding TKI, or switching to a different therapy?
Answer from: Medical Oncologist at Academic Institution
It appears that it has been two years since the last platinum therapy (progressed after 1 year, then on immunotherapy for one year) so it's very reasonable to consider the use of platinum-based chemotherapy again, an option could include platinum + taxane + bevacizumab to add a targeted therapy to t...
Sign in or Register to read more